5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study - Wikidata - awgldk - TriplyDB

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

http://www.wikidata.org/entity/Q28182523

about

Colitis-associated colon cancer: Is it in your genes?Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Ulcerative colitis-associated colorectal cancer Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines The therapeutic value of targeting inflammation in gastrointestinal cancers Mesalazine in inflammatory bowel disease: a trendy topic once again?The actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repair Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.Cancer surveillance strategies in ulcerative colitis: the need for modernization.Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging.5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis.Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.Systematic review: the use of mesalazine in inflammatory bowel disease.Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey.Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.Update in the treatment of paediatric ulcerative colitis.The role of mesalamine in the treatment of ulcerative colitis.Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006.Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry Quality of life of patients with ulcerative colitis: past, present, and future.The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ.Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease.Targeting NF-kappaB for colorectal cancer.Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study.MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.Potential avenues for immunotherapy of colitis-associated neoplasia.Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.

P2860

Q26778018-F652F864-C809-4C9C-B2D6-3D5C5DEC923D Q26785537-C8609BEE-6C2E-4AE2-AABC-46B8540FB8AB Q26822499-9DB7440A-8EAD-4286-A433-9750AD77B15D Q26864562-82C97591-F91E-40B2-B42E-966E40D1DFB2 Q27024203-3A15A376-AFED-4B87-9A76-4C8D8662A96B Q33779797-F2BB7134-8702-4A99-88AD-45D936A879E1 Q33827631-346AEF07-73E0-422B-BCED-2B030704BB85 Q33950898-D6E3DED7-ED32-4E54-8DCF-E63F7D6D51AB Q34150651-5697F973-F1FD-47B9-AA2D-F8F4A4C6D39C Q34275396-8C9C8E67-DBC2-4A67-8134-493F94D4FA82 Q34587817-911CE575-285D-4B4E-AE96-564001A2717C Q35142116-2935103E-18E0-4094-92C6-718BF92E5272 Q35619921-49308B45-7008-4E65-8629-F4FF38E2444C Q35943219-2F967F9E-414B-4062-897A-D05650FA42BF Q36144377-85132B75-56DA-4667-86E2-DECD29978DC2 Q36367384-F0DDDE03-D1BF-45A0-A501-481ECC502CEA Q36435889-9C7B58CD-C2B8-44D6-B3EA-C8DDC0CBAA23 Q36468969-DE083640-B748-4AB8-8F24-718DA3F3E915 Q36555966-96CE1ED0-486B-43C6-B4BD-906473BA9092 Q36580628-3A0DAF2C-6EFB-4AE3-8B93-747BB7F03EE3 Q36589432-1B9B218C-40F8-407D-8D23-09648EB58590 Q36613876-A957B668-0421-434C-88C9-7C533771DCA3 Q36645826-2BE6445D-CFA9-4591-80D9-7B3C28296FC2 Q36739682-72B73AAA-B64D-4D77-92B6-C9576FBFA57D Q36747550-09CBDFB9-78F9-4562-91F6-4E1406C1F44C Q36897912-F7A69A8B-EEB2-42EF-AE69-F7397BBFA1CC Q36987080-D89CDBCA-ABAF-43EA-BFAA-A4EA011060A7 Q37262181-B816D1BA-C87F-46F9-A8B1-C6E84065CF09 Q37305789-079F20DC-0E16-498D-A3A0-F77083F7944D Q37393339-06D9B860-012F-4B85-A698-AD71A5FBB778 Q37692380-8D44CE1E-7DF7-433E-99B9-FB4BA1DCD36D Q37724387-D473EE8B-9150-4C2D-B684-0EEDCADB457A Q37725987-CC1AA4B8-1F7F-46EE-AABB-572E85C190B2 Q37786311-9D4A5AF6-B2A3-4963-8B59-35B555C0F22A Q37806620-A9E70620-4D57-4766-A740-A07642746FDE Q37833064-34A0D0D8-A442-4DBE-8D96-29BD9CEE4704 Q37885729-DF7E318E-1BA1-4534-8AB1-24EFDC39A7B8 Q37892884-B24267FB-666D-47EE-9D36-12836AEE62DA Q38003476-2EE149C7-7010-4646-B3D4-C8CDC4AFCC3B Q38049779-E1056A58-41AF-4CB5-80FD-CA52756879E2

P2860

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

http://www.wikidata.org/entity/Q28182523

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

5-Aminosalicylate use and colo ...... a large epidemiological study

@ast

5-Aminosalicylate use and colo ...... a large epidemiological study

@en

5-Aminosalicylate use and colo ...... a large epidemiological study

@nl

type

label

5-Aminosalicylate use and colo ...... a large epidemiological study

@ast

5-Aminosalicylate use and colo ...... a large epidemiological study

@en

5-Aminosalicylate use and colo ...... a large epidemiological study

@nl

prefLabel

5-Aminosalicylate use and colo ...... a large epidemiological study

@ast

5-Aminosalicylate use and colo ...... a large epidemiological study

@en

5-Aminosalicylate use and colo ...... a large epidemiological study

@nl

P1433

Q28182523-941C0AE1-1710-4806-8DEC-749640E995C6

P1476

Q28182523-068B1D01-0A87-49BC-9ED4-D768F1167F1D

P2093

Q28182523-90B6DB8B-ED6C-4C10-9B42-02380D2C259A

Q28182523-BBB9CBBB-CB1A-4A1E-A697-BF3BDA605A93

Q28182523-E3D578D2-565C-401C-95B0-57A3EF230887

P2860

Q28182523-11DF5459-7F7D-4B0B-A973-9ADDFB689543

Q28182523-1BDFE899-059F-4DFD-91AA-EB94B582A34F

Q28182523-1E5B3AB6-C470-4C6E-A0ED-6367A808820E

Q28182523-60895EE8-E9B6-4183-939C-682249A1A18D

Q28182523-60B0C343-639E-43EB-8300-E0B7AB84B8A4

Q28182523-83D8B9FF-FEE6-43F5-8620-297B5B7BD6F8

Q28182523-92500447-B3EF-4E57-8FEF-5366DFA2ABF1

Q28182523-9646CE5E-A8E4-4CFD-8C9F-F8BA00DF889E

Q28182523-A4B69D34-CDBE-4EAD-A2D9-0251DDDB28CE

Q28182523-A6F53CA0-57D3-4154-B856-CD60B7E1BA8D

P304

Q28182523-EA5F360D-179F-4033-A312-68D7D7D16519

P31

Q28182523-F365B9EB-7DFC-4169-9EAD-029AA9CA8D5D

P356

Q28182523-1DCC57A1-1BE3-4A7D-8249-3C87E670C0D4

P407

Q28182523-6BE42AC0-417C-468F-8D4B-14BFF18BAD2A

P433

Q28182523-9290C5E4-55D5-4917-8DFD-744EC6BB6882

P478

Q28182523-1F3BF7CA-B580-411F-8441-D9977B6CB629

P50

Q28182523-F51403FA-9B09-42EA-B9E6-42006EFE3EFB

P577

Q28182523-E0380D36-9C12-4E10-BA51-7966DD923BF8

P5875

Q28182523-B3C27533-267E-431E-8AF7-3508876D4C09

P698

Q28182523-14C28B72-CA99-42C4-B059-91E97A659189

P921

Q28182523-97F3BC5F-ABD2-4739-8A18-777945586BF8

Q28182523-ADB8A7E2-FF4D-40DA-A30F-296F006565A4

Q28182523-D9A138F9-E8D9-49C2-925E-8A4D5FE5E54C

P932

Q28182523-BAA10DDB-F1E6-4FB0-BD1D-9B8F0DF64FAB

P356

GUT.2005.070896

P1433

P1476

5-Aminosalicylate use and colo ...... a large epidemiological study

@en

P2093

H G M Leufkens

http://www.w3.org/2001/XMLSchema#string

R F Logan

http://www.w3.org/2001/XMLSchema#string

T P van Staa

http://www.w3.org/2001/XMLSchema#string

P2860

The risk of colorectal cancer in ulcerative colitis: a meta-analysis

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

A randomized trial of aspirin to prevent colorectal adenomas

Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas

Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial

Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease.

Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.

Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.

Colorectal cancer prevention in ulcerative colitis: a case-control study.

Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.

P304

1573-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2005.070896

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Timothy R. Card

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7750382

http://www.w3.org/2001/XMLSchema#string

P698

15994215

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

inflammatory bowel diseases

P932

1774734

http://www.w3.org/2001/XMLSchema#string